First Manhattan
BNTX icon

First Manhattan’s BioNTech BNTX Stock Holding History

First Manhattan’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-725
Closed -$66.9K – 747
2024
Q1 		$66.9K Buy
725
+76
+12% +$7.29K ﹤0.01% 832
2023
Q4 		$68.5K Buy
649
+149
+30% +$15K ﹤0.01% 813
2023
Q3 		$54.3K Hold
500
– – ﹤0.01% 854
2023
Q2 		$54K Hold
500
– – ﹤0.01% 875
2023
Q1 		$62.3K Hold
500
– – ﹤0.01% 881
2022
Q4 		$75.1K Hold
500
– – ﹤0.01% 871
2022
Q3 		$67K Hold
500
– – ﹤0.01% 889
2022
Q2 		$74K Hold
500
– – ﹤0.01% 898
2022
Q1 		$85K Hold
500
– – ﹤0.01% 910
2021
Q4 		$128K Hold
500
– – ﹤0.01% 828
2021
Q3 		$136K Hold
500
– – ﹤0.01% 811
2021
Q2 		$111K Hold
500
– – ﹤0.01% 837
2021
Q1 		$54K Buy
+500
New +$53.1K ﹤0.01% 942

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan's BNTX Position: Q2 2024 in Review

First Manhattan sold out of BioNTech (BNTX) in Q2 2024, closing a stake of 725 shares — an estimated $66.9K sold.

First Manhattan first reported a position in BNTX in Q1 2021 and held it in 13 quarters. The position peaked at $136K in Q3 2021. 286 funds tracked by Wall St. Rank hold BNTX as of Q2 2024.

  • First Manhattan reported no remaining BioNTech position as of Q2 2024 after selling out during the quarter.
  • First Manhattan sold 725 BioNTech shares in Q2 2024, an estimated $66.9K.
  • First Manhattan first reported a position in BioNTech in Q1 2021 and held it in 13 quarters.
  • First Manhattan's BioNTech position peaked at $136K in Q3 2021.
  • 286 funds tracked by Wall St. Rank held BioNTech as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.